NTLA FY 2019 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M+41.6% YoY

Gross Profit

-$65M-151.5% margin

Operating Income

-$106M-246.8% margin

Net Income

-$100M-230.9% margin

EPS (Diluted)

$-1.96

Cash Flow

Operating Cash Flow

-$103M

Free Cash Flow

-$110M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$334M

Total Liabilities

$64M

Stockholders' Equity

$270M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$30M	+41.6%
Gross Profit	-$65M	-$59M	-11.3%
Operating Income	-$106M	-$91M	-17.1%
Net Income	-$100M	-$85M	-16.6%